These findings indicate that CC AM cells harbor tumor-initiating cells that are responsible for AM recurrence and that targeting EZH2 suppresses the stemness of AM cells, suggesting that inhibition of EZH2 is a promising approach for AM treatment. Here, EZH2 is linked to neoplasm.